Short Interest in Roivant Sciences Ltd. (NASDAQ:ROIV) Increases By 25.3%

Roivant Sciences Ltd. (NASDAQ:ROIV) saw a significant increase in short interest in January. As of January 15th, there was short interest totaling 24,529,353 shares, an increase of 25.3% from the December 31st total of 19,579,958 shares. Currently, 4.0% of the shares of the stock are sold short. Based on an average daily volume of 6,681,612 shares, the days-to-cover ratio is currently 3.7 days. Based on an average daily volume of 6,681,612 shares, the days-to-cover ratio is currently 3.7 days. Currently, 4.0% of the shares of the stock are sold short.

Roivant Sciences Stock Up 1.2%

Shares of NASDAQ:ROIV traded up $0.26 during midday trading on Monday, reaching $21.88. 3,974,012 shares of the company were exchanged, compared to its average volume of 5,550,282. The firm has a market cap of $15.22 billion, a PE ratio of -39.00 and a beta of 1.22. Roivant Sciences has a fifty-two week low of $8.73 and a fifty-two week high of $23.91. The stock has a fifty day simple moving average of $21.89 and a two-hundred day simple moving average of $17.47.

Insider Activity at Roivant Sciences

In related news, major shareholder Vivek Ramaswamy sold 353,745 shares of Roivant Sciences stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $22.05, for a total value of $7,800,077.25. Following the completion of the sale, the insider directly owned 34,132,463 shares in the company, valued at $752,620,809.15. This trade represents a 1.03% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Daniel Allen Gold sold 777,332 shares of the business’s stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $23.07, for a total transaction of $17,933,049.24. Following the sale, the director directly owned 16,353,113 shares of the company’s stock, valued at approximately $377,266,316.91. This trade represents a 4.54% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 12,332,392 shares of company stock valued at $266,393,645. 10.80% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Roivant Sciences

Hedge funds have recently made changes to their positions in the business. Sandro Wealth Management LLC bought a new stake in shares of Roivant Sciences in the fourth quarter worth $1,959,000. Horizon Investments LLC acquired a new stake in Roivant Sciences in the 4th quarter valued at $125,000. Fifth Third Bancorp lifted its position in Roivant Sciences by 15.8% during the 4th quarter. Fifth Third Bancorp now owns 4,310 shares of the company’s stock worth $94,000 after buying an additional 588 shares in the last quarter. New York State Teachers Retirement System boosted its stake in shares of Roivant Sciences by 5.6% during the 4th quarter. New York State Teachers Retirement System now owns 270,221 shares of the company’s stock worth $5,864,000 after buying an additional 14,300 shares during the last quarter. Finally, Jennison Associates LLC bought a new position in shares of Roivant Sciences in the 4th quarter valued at about $51,068,000. 64.76% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. Citigroup raised their price target on Roivant Sciences from $25.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, November 11th. Wall Street Zen upgraded Roivant Sciences from a “strong sell” rating to a “hold” rating in a report on Sunday, November 16th. Leerink Partners upped their price target on Roivant Sciences from $29.00 to $32.00 and gave the company an “outperform” rating in a research note on Monday, December 15th. Guggenheim reissued a “buy” rating and set a $28.00 price objective on shares of Roivant Sciences in a research note on Thursday, December 18th. Finally, The Goldman Sachs Group upped their target price on shares of Roivant Sciences from $24.00 to $33.00 and gave the company a “buy” rating in a research note on Monday, December 15th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $25.19.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.